Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION After a boxed-warning proposal from the review division, disproportionate reporting signal workbook is what regulatory-affairs lead can touch in a rare-disease team designing a pediatric plan. Pharma & Life Sciences will live with Proceed under protocol versus Pause the pathway on this Pharmacovigilance file.

DECISION Regulatory-affairs lead in a rare-disease team designing a pediatric plan must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using disproportionate reporting signal workbook after a boxed-warning proposal from the review division.

HYPOTHESES TO TEST 1. Disproportionate reporting signal workbook reads as Proceed under protocol once a boxed-warning proposal from the review division is lined up to the same Pharma & Life Sciences population. 2. Disproportionate reporting signal workbook is closer to Pause the pathway after a boxed-warning proposal from the review division; Proceed under protocol would over-claim this Pharmacovigilance extract. 3. Escalate safety review is still live in disproportionate reporting signal workbook for regulatory-affairs lead in a rare-disease team designing a pediatric plan. 4. Disproportionate reporting signal workbook is missing the fact regulatory-affairs lead needs after a boxed-warning proposal from the review division; stop this Pharma & Life Sciences close.

ANALYSIS REQUIRED 1. Separate an isolated adverse event from a systemic quality issue. 2. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 3. Check whether disproportionate reporting signal workbook supports the labeled claim regulatory-affairs lead would keep. 4. For this Pharma & Life Sciences Pharmacovigilance file, read disproportionate reporting signal workbook against a boxed-warning proposal from the review division and write the one fact that would move to drop a secondary for regulatory-affairs lead.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Pharmacovigilance packet (disproportionate reporting signal workbook after a boxed-warning proposal from the review division). The follow-on Pharmacovigilance action is what regulatory-affairs lead does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in disproportionate reporting signal workbook, then the action for regulatory-affairs lead - Hypothesis scorecard against disproportionate reporting signal workbook: supported / rejected / untestable - Regulatory or exam hook Pharmacovigilance would cite - Pharmacovigilance finding in disproportionate reporting signal workbook that a second reviewer can re-perform